Please assess the completion status of the following clinical trial:

Trial Title: GVAX® Vaccine for Prostate Cancer vs Docetaxel & Prednisone in Patients With Metastatic Hormone-Refractory Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of or clinical history consistent with adenocarcinoma of the prostate~* Metastatic prostate cancer deemed to be unresponsive or refractory to hormone therapy~* Detectable metastases~* Any Gleason score~* ECOG performance status 0-2~Exclusion Criteria:~* Prior treatment with chemotherapy~* Prior Immunotherapy~* Prior treatment with gene therapy~* Significant cancer related pain

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 2 (Type: OTHER): Standard of care - chemotherapy
- 1 (Type: EXPERIMENTAL): Immunotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).